Engineering biopharmaceuticals

BioPharm International

Volumn 20, Issue 11, 2007, Pages 64-68

  Walsh, Gary ^a  

^a UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BEVACIZUMAB; CETUXIMAB; EFALIZUMAB; ETANERCEPT; IMIGLUCERASE; INSULIN DETEMIR; INSULIN GLULISINE; INSULIN LISPRO; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMALIZUMAB; PALIFERMIN; PARATHYROID HORMONE[1-34]; PEGINTERFERON ALPHA2A; PEGVISOMANT; RANIBIZUMAB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

ACROMEGALY; ANEMIA; ASTHMA; BIOLOGICAL ACTIVITY; BIOMEDICAL ENGINEERING; COLORECTAL CANCER; DIABETES MELLITUS; DRUG MANUFACTURE; HEPATITIS C; HUMAN; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PROTEIN ENGINEERING; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PSORIASIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SEQUENCE ANALYSIS; STOMATITIS;

EID: 37349006886     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (8)

1. Walsh, G. Second-generation biopharmaceuticals. Eur. J Pharm. Biopharm. 2004;58:185-196
2. Walsh, G. and Jefferis, R. Posttranslational modifications in the context of therapeutic proteins. Nature Biotechnol. 2006;24:1241-1252
3. Kobata, A. Structure and function of the sugar chains of glycoproteins. Eur. J Biochem. 1992;209:483-501
4. Dwek, R., Butters, T. Platt, F., Zitzmann, N. Targeting glycosylation as a therapeutic approach. Nature Rev. Drug Discov. 2002;1:65-75
5. Wildt, S. and Gerngross, T. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 2005;3:119-128.
6. Li, H., Sethuraman, N., Stadheim, T., Zha, D., Prinz, B. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. biotechnol. 2006;24:210-215.
7. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Progress, 2005;21:11-16.
8. Satoh, M., Iida, S. and Shitara, K. Non-fucosylated therapeutic antibodies as next generation therapeutic antibodies. Exp. Op. Biol. Ther. 2006;6:1161-1173.